XTX Topco’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

XTX Topco’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-29,766	Closed	-$125K	–	1484
2022 Q2	$125K	Buy	+29,766	New	+$118K	0.05%	595
2022 Q1	–	Sell	-14,305	Closed	-$45K	–	1035
2021 Q4	$45K	Buy	+14,305	New	+$47.6K	0.03%	577
2021 Q2	–	Sell	-30,110	Closed	-$150K	–	1181
2021 Q1	$150K	Buy	+30,110	New	+$243K	0.07%	530

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

XTX Topco's CNCE Position: Q3 2022 in Review

XTX Topco sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2022, closing a stake of 29,766 shares — an estimated $125K sold.

XTX Topco first reported a position in CNCE in Q1 2021 and held it in 3 quarters. The position peaked at $150K in Q1 2021. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2022.

XTX Topco reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
XTX Topco sold 29,766 Concert Pharmaceuticals, Inc. shares in Q3 2022, an estimated $125K.
XTX Topco first reported a position in Concert Pharmaceuticals, Inc. in Q1 2021 and held it in 3 quarters.
XTX Topco's Concert Pharmaceuticals, Inc. position peaked at $150K in Q1 2021.
80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2022.

Based on XTX Topco's 13F filing for Q3 2022, filed 14 Nov 2022.